Purpose: In development, chondrocyte hypertrophy is a crucial and well-studied step in endochondral ossification. Hypertrophy may also play a role in pathophysiological processes, including osteoarthritis. We employ a computational approach to estimate the effect of individual factors in this complex process. Methods: We have combined information gleaned from a high number of publications on chondrocyte differentiation into a gene regulatory network of 46 factors and over 150 interactions. This network can estimate the stability of proliferative chondrocytes/permanent cartilage (stable state with SOX9 activity) and hypertrophic chondrocytes (stable state with RUNX2 activity) by employing 2 measures. A first measure is a Monte Carlo analysis that assesses stability in the face of random initial conditions, the second modifies stable states to estimate the sensitivity to perturbation. Results: For each factor, these qualitative measures are calculated in silico under knockout and overexpression conditions and compared to the wild type situation. This enables screening of the effects of all incorporated factors on cartilage homeostasis, differentiation and pathogenesis via the initiation of hypertrophy. Indeed, our gene network analysis indicated multiple candidate genes for the development of osteoarthritis. Factors that amplify the SOX9 attractor basin include TGFb, PPR, IGF-I, and PKA. The presence of RAS, IHH, GLI2 and FGF is required for the Runx2 stable state. Using a literature study, we corroborated several of the proposed factors. Conclusions: In silico screening of overexpression and knockout presents a novel strategy to improve bone and cartilage tissue engineering approaches, and can be used to propose a list of putative therapeutic targets for e.g. osteoarthritis.
Purpose: In development, chondrocyte hypertrophy is a crucial and well-studied step in endochondral ossification. Hypertrophy may also play a role in pathophysiological processes, including osteoarthritis. We employ a computational approach to estimate the effect of individual factors in this complex process. Methods: We have combined information gleaned from a high number of publications on chondrocyte differentiation into a gene regulatory network of 46 factors and over 150 interactions. This network can estimate the stability of proliferative chondrocytes/permanent cartilage (stable state with SOX9 activity) and hypertrophic chondrocytes (stable state with RUNX2 activity) by employing 2 measures. A first measure is a Monte Carlo analysis that assesses stability in the face of random initial conditions, the second modifies stable states to estimate the sensitivity to perturbation. Results: For each factor, these qualitative measures are calculated in silico under knockout and overexpression conditions and compared to the wild type situation. This enables screening of the effects of all incorporated factors on cartilage homeostasis, differentiation and pathogenesis via the initiation of hypertrophy. Indeed, our gene network analysis indicated multiple candidate genes for the development of osteoarthritis. Factors that amplify the SOX9 attractor basin include TGFb, PPR, IGF-I, and PKA. The presence of RAS, IHH, GLI2 and FGF is required for the Runx2 stable state. Using a literature study, we corroborated several of the proposed factors. Conclusions: In silico screening of overexpression and knockout presents a novel strategy to improve bone and cartilage tissue engineering approaches, and can be used to propose a list of putative therapeutic targets for e.g. osteoarthritis. Purpose: Transforming growth factor-beta (TGF-b) is a multifunctional growth factor that maintains cartilage integrity and function by promoting synthesis of extracellular matrix (ECM) proteins such as type II collagen. Dysregulation of TGF-b action is implicated in joint diseases such as osteoarthritis (OA). TGF-b initiates its action by binding to the type II TGF-b receptor which then phosphorylates and activates type I receptor (Activin-receptor Like Kinase 5, ALK5) which in turn phosphorylates the intracellular proteins, Smad2/3. The activated Smad2/3 then forms a heteromeric complex with Smad4 and translocates to the nucleus leading to regulation of gene transcription. Our group has reported the discovery of CD109 as a novel TGF-b co-receptor and has shown that CD109 is a potent negative regulator of TGF-b signaling and action in skin. The objectives of the current study were: (i) to determine whether CD109 is expressed in human articular chondrocytes, and (ii) to examine whether CD109 regulates TGF-b signaling and ECM protein expression in human articular chondrocytes. Methods: Articular chondrocytes were isolated from normal cartilage harvested from adult patients with traumatic open joint injury who have no history of OA or from osteoarthritic cartilage obtained from OA patients at hip replacement surgery. CD109 expression in chondrocytes was determined by Western blot and CD109 function was analyzed by blocking CD109 expression using CD109-specific siRNA and measuring TGF-b-induced transcriptional activity, Smad phosphorylation, and production of ECM proteins, type II collagen and plasminogen activator inhibitor-1 (PAI-1). Results: Our results show that CD109 is expressed in human articular chondrocytes and that CD109 markedly decreases type I TGF-b receptor (ALK5) expression and inhibits TGF-b-induced phosphorylation of Smad3, Smad3-driven transcriptional activity, and expression of type II collagen and PAI-1. Conclusions: Our findings suggest that CD109 negatively regulates TGF-b signaling and TGF-b-induced ECM protein production in human articular chondrocytes, and may play an important role in maintaining cartilage function and integrity. Purpose: Aggrecan, the main proteoglycan of articular cartilage, enables the tissue to resist compression. In health, aggrecan synthesis is balanced by its turnover. In arthritis, there is a net degradation, thought mainly to be due to an increase in proteolytic activity in the joint. Loss of aggrecan is a feature of arthritic cartilage and can be induced experimentally by various stimuli including pro-inflammatory cytokines such as IL1. IL1 induces specific aggrecan cleavages at sites where ADAMTS proteinases characteristically act. Here, we aimed to identify the intracellular signalling pathways by which IL1 controls aggrecan degradation by human chondrocytes, and the mechanism of this control, particularly focusing on the regulation of extracellular aggrecanases by the cell receptor Low density lipoprotein receptor-related protein 1 (LRP1). Methods: We developed a cell-based assay that combines siRNAinduced knockdown with an aggrecan degradation assay. Human articular chondrocytes were overlaid with bovine aggrecan in combination with siRNAs against key proteins in the IL1 signalling pathway. Knockdown efficiency was analysed by Western blotting or by RT-PCR. NFkB activation was inhibited by infection with an IkB virus. Aggrecan fragments in the culture medium were identified by antibodies to the AGEG and ARGS cleavage neo-epitopes. Total aggrecanase activity and TIMP3 levels were measured by ELISA. LRP-1 shedding was analysed by western blotting. Results: By siRNA, we show that ADAMTS5 is the major aggrecanase in human chondrocytes following IL1 stimulation. The TRAF6/TAK1/MKK4 signalling axis is essential for IL1 induced aggrecan degradation, while NFkB is not. Of the three MAPK kinases; ERK, p38 and JNK, only JNK2 showed a significant role in aggrecan degradation. JNK2 had no effect on mRNA levels of Adamts5. IL1 caused aggrecanase activity to appear in the medium in a JNK2-dependent manner, possibly by reducing its endocytosis, since IL-1 caused JNK2-dependent shedding of LRP-1. In unstimulated cells, basal levels of aggrecanases were kept low by continuous endocytic activitity through LRP1.
Conclusions:
The results demonstrate an essential role for the signaling axis TRAF6/TAK1/MKK4/JNK2 in IL1 induced aggrecanolysis. Knockdown of JNK2 significantly reduced the detectable levels of aggrecanases in culture medium and could control its endocytosis. JNK2 could exert its effects on aggrecan degradation through regulation of LRP1mediated endocytosis of aggrecanses. Purpose: We have recently demonstrated that ELRþ CXC chemokines, which signal via the CXCR2 receptor, are produced by healthy chondrocytes and are retained within the cartilage matrix via interactions with heparan sulfate proteoglycans. Here, they act to support articular cartilage homeostasis by inducing AKT phosphorylation, thus increasing chondrocyte survival, SOX9 expression and extracellular matrix production, particularly during conditions of physiological challenge, indicated by increased chondrocyte apoptosis and cartilage degradation in CXCR2-/-mice following destabilization of the medial meniscus. Interestingly, the transient receptor potential channel 6 (TRPC6) ion channel has been shown to be a specific mediator of CXCR2 driven cell migration via AKT signaling. This project aims to investigate whether TRPC6 is involved in the mechanism of CXCR2-mediated control of chondrocyte phenotypic stability via calcium signaling pathways. Methods: Costal chondrocytes were isolated from CXCR2-/-mice, TRPC6-/-mice and their wild type littermates and expanded in Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A152
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